Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO golimumab prolonged-interval pharmacokinetics study
NL-OMON48335Phase 4Not yet recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in rheumatism, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 1 more, sponsored by Sint Maartenskliniek. Primary endpoints: Golimumab serum peak level, Golimumab serum trough level and 1 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
golimumab
03
Conditions
rheumatismrheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON48335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48335.